REGN logo
REGN NASDAQ US

Regeneron Pharmaceuticals, Inc. - Common Stock

Healthcare · Biotechnology Website · IPO Apr 1991
$761.85
▼ $-15.40 (-1.98%)
Vol 1.0M
11
Quality Score
ok
Deep Check
2/5 ok
Mkt Cap
$81.1B
P/E
17.7
ROE
15.3%
Margin
32.1%
D/E
8.74
Beta
0.40
Div Yield
0.46%
52W
$476–$793

Wall Street Consensus

38 analysts · Apr 2026
11
Strong Buy
19
Buy
8
Hold
0
Sell
0
Strong Sell
78.9%
Buy Rating

Price Chart

Similar Stocks

AMGN
Amgen Inc
P/E 25.2
$176.3B
GILD
Gilead Sciences Inc
P/E 18.8
$152.3B
VRTX
Vertex Pharmaceuticals Inc
P/E 31.3
$115.0B
ALNY
Alnylam Pharmaceuticals Inc
P/E 1205.9
$52.5B
INSM
Insmed Inc
$37.1B
NTRA
Natera Inc
$31.7B
BIIB
Biogen Inc
P/E 16.0
$25.8B
UTHR
United Therapeutics Corp
P/E 16.5
$21.0B

Earnings

Beat rate: 75.0%
Quarter EPS Est EPS Act Surprise
Dec 2025 $10.83 $11.44 +$0.61
Sep 2025 $9.78 $11.83 +$2.05
Jun 2025 $8.61 $12.89 +$4.28
Mar 2025 $9.00 $8.22 $-0.78

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) 15.1% 15.1% 15.1% 15.3% 15.3% 15.3%
P/E (TTM) 12.71 13.68 14.33 14.96 17.03 17.72
Net Margin 37.9% 31.4% 31.4% 32.1% 32.1% 32.1%
Gross Margin 85.6% 86.5% 86.5% 86.3% 86.3% 86.3%
D/E Ratio 9.04 9.04 9.04 8.74 8.74 8.74
Current Ratio 4.60 4.60 4.60 4.06 4.06 4.06

Key Ratios

ROA (TTM)
11.9%
P/S (TTM)
5.69
P/B
2.7
EPS (TTM)
$41.78
CF/Share
$38.82
Rev Growth 3Y
-4.0%
52W High
$792.77
52W Low
$476.49
$476.49 52-Week Range $792.77

How does REGN compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

REGN AAPG ABEO ABOS ABP

REGN valuation vs Biotechnology peers

P/E ratio
17.7
▼ 6% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
5.7
▼ 56% below peers (12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
2.7
▲ 8% above peers (2.5)
vs Peers
vs Industry
Fair value
Div yield
0.5%
▼ 0% below peers (0.0%)
vs Peers
vs Industry
Low yield

REGN profitability vs Biotechnology peers

ROE
15.3%
▲ 123% above peers (-67.3%)
vs Peers
vs Industry
Top tier
Net margin
32.1%
▲ 111% above peers (-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
86.3%
▲ 10% above peers (78.6%)
vs Peers
vs Industry
Weak
ROA
11.9%
▲ 125% above peers (-46.7%)
vs Peers
vs Industry
Top tier

REGN financial health vs Biotechnology peers

D/E ratio
8.7
▼ 0% below peers (0.0)
vs Peers
vs Industry
High debt
Current ratio
4.1
▼ 8% below peers (4.4)
vs Peers
vs Industry
In line
Beta
0.4
▼ 59% below peers (1.0)
vs Peers
vs Industry
More volatile

REGN fundamentals radar

REGN Peer median Industry

REGN profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

REGN vs peers: key metrics

Related Signals

Bounce Up
$703.26 2.00x Dec 09

Latest News

Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement
Nasdaq · Mar 19
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?
Yahoo Finance · Mar 17